Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 8, 2022. In addition to the statistically significant CGI-C and PGI-C in the XEN1101 25 mg group, the XEN1101 20 mg group was statistically significant in PGI-C, while the XEN1101 20 mg group in CGI-C and the XEN1101 10 mg group for both CGI-C and PGI-C showed numerical improvements over placebo but were not statistically significant. Tovbbi informcirt s a belltsi lehetsgek kezelshez kattintson a Belltsok kezelse gombra. . Prior to joining us, Ms. McCloskey was Vice President, Human Resources and Administration at Aquinox Pharmaceuticals, Inc. from 2015 to 2018. James Empfield , Ph.D. Executive Vice President, Drug Discovery. Prior to joining us, since March 2013, Ms. Grant was Chief Operating Officer at Correvio Pharma Corp. (previously Cardiome Pharma Corp.), which was acquired by ADVANZ PHARMA Corp. Limited in May 2020. Ms. DiFabio has served as our Chief Legal Officer and Corporate Secretary since November 2022. in Psychology and an Education Diploma from the University of British Columbia. Fax: 604.484.3450 We manufacture, trading, supply, deliver pharmaceutical molecules. This is an in-house version of XEN496, a Kv7 potassium channel modulator that Xenon . These marked reductions in seizures were associated with statistically significant improvements in overall status, as assessed by physicians using the Clinical Global Impression of Change (CGI-C) and by subject self-reporting using the Patient Global Impression of Change (PGI-C) scales in the XEN1101 25 mg group, which are shown in the table below with 2-sided p-values: XEN1101 was generally well-tolerated in this study with adverse events (AEs) consistent with other ASMs. A Ray of Hope During the Covid-19 CRISIS. In other news Xenon Pharmaceuticals has a 12 month low of $23.26 and a 12 month high of $41.39. Ms. Grant holds an MBA degree from Simon Fraser University and an MSc from the London School of Hygiene and Tropical Medicine. . En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. XENON has been on the front lines in the battle against Covid-19. Previously, Dr. Kenney was Senior Vice President of Medical Affairs (2018-2019) and Senior Vice President, Clinical Development (2016-2018) at Acorda Therapeutics. After the downgrade, the consensus from Xenon Pharmaceuticals' twelve analysts is for revenues of US$10m in 2023, which would reflect a painful 22% decline in sales compared to the last year of . Ms. Aulin holds a BCom from the University of British Columbia and is a Chartered Professional Accountant, Chartered Accountant. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. Xenon Pharmaceuticals XENE is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Royal Bank of Canada increased their price objective on shares of Xenon Pharmaceuticals from $46.00 to $49.00 and gave the company an "outperform . Xenon Pharmaceuticals' recent stock market performance was driven by clinical trial success for XEN1101. Chief Legal Officer and Corporate Secretary. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Subjects had an average age of 40.8 13.3 years, and 8.9%, 40.3%, or 50.8% of the subjects were on and continued taking one, two, or three stable background anti-seizure medications (ASMs) throughout the study, respectively, and failed a median of 6 previous ASMs prior to study entry. Previously, Ms. Grant was Cardiome's VP of Product Development, with the responsibility for the overall management of the vernakalant IV and oral programs. Xenon Pharmaceuticals Inc's stock is up 24.3% in 2022, up 6.5% in the previous five trading days and up 50.27% in the past year. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. See insights on Xenon Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Through his tenure from 2008 to 2019 at ClearView, Dr. info@xenon-pharma.com. Find the latest Xenon Pharmaceuticals Inc. (XENE) stock quote, history, news and other vital information to help you with your stock trading and investing. Fax: 604.484.3450 BURNABY, British Columbia (AP) _ Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $37.2 million in its third quarter. Von Seggern is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Chief Commercial Officer since August 2020. These 4 analysts have an average price target of $50.0 versus the current price of Xenon Pharmaceuticals at $35.75, implying upside. Von Seggern worked across the pharmaceutical sector with emphasis in orphan diseases and transformational technologies. We use the most advanced manufacturing techniques and technology to create a product range that is both The monotonic dose response relationship between the XEN1101 active dose groups compared to placebo was statistically significant (p<0.001). Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; any of our or our collaborators product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. This role is crucial in coordinating the integration of end-to-end workflow from purchase order to payments at Xenon Pharmaceuticals including vendor onboarding, purchase order creation and approvals, invoicing, and payment resolutions. in Chemistry from Bucknell University and a B.Sc. About Xenon Pharma. Benzinga Pro data, Xenon Pharmaceuticals XENE reported Q3 sales of $132 thousand. Most recently, Dr. Kenney served as Chief Medical Officer at Cadent Therapeutics, a biotech company focused on creating breakthrough therapies for neurological and psychiatric conditions, from 2019 until December 2020 when it was acquired by Novartis. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Ms. Sheila Grant has served as our Executive Vice President, R&D Operations since January 2022, and has led our R&D Operations function since joining Xenon in August 2020. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The most common TEAEs across all XEN1101 dose groups (n=211) were dizziness (n=52, 24.6%), somnolence (n=33, 15.6%), fatigue (n=23, 10.9%), and headache (n=21, 10.0%). Mr. Mortimer previously served as our Corporate Secretary from June 2015 to March 2021, as our Chief Financial Officer and Chief Operating Officer since March 2015 and as our Chief Financial Officer since October 2013. Below is a summary of how these 4 analysts rated Xenon . We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Insider Transactions at Xenon Pharmaceuticals. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. For more information, please visit www.xenon-pharma.com. Since July 2020, Mr. Mortimer has served on the board of directors of Perimeter Medical Imaging AI, Inc., a publicly-traded medical device company focused on advanced in procedural medical imaging tools. Conference Call InformationXenon will host a conference call and live webcast with slides today at 7:30 am Eastern Time (4:30 am Pacific Time) to discuss the topline results from the XEN1101 Phase 2b X-TOLE clinical trial. Xenon Pharmaceuticals is running a phase 3 trial with GlaxoSmithKline's castoff for the treatment of a small, genetically defined group of epilepsy patients who are likely to respond to Kv7 . Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary November 7 . Dr. Empfield joined Xenon in 2016 and is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., as our Executive Vice President, Drug Discovery. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. info@xenon-pharma.com. Dr. 3650 Gilmore Way The incidence of treatment-emergent serious adverse events (SAEs) was similar in all four arms of the study with 2.6% of patients in the placebo group, 4.3% of patients in the XEN1101 10 mg group, 3.9% of patients in the XEN1101 20 mg group, and 2.6% of patients in the XEN1101 25 mg group experiencing at least one treatment-emergent SAE. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Xenon Pharmaceuticals Inc. announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). Of importance, the XEN1101 efficacy data are especially compelling given that approximately 50% of the subjects in X-TOLE were using three concomitant ASMs, suggesting that this was potentially an even more challenging patient population than previous studies with other ASMs. Sie knnen Ihre Einstellungen jederzeit ndern. . Copyright 2001 2022 Xenon All rights reserved. With these compelling topline results, we are eager to work with the FDA to plan for an expedited development path moving forward.. Earnings fell to a loss of $37.15 million, resulting in a 19.23% decrease from last quarter. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. From 2004 to 2011, Ms. Aulin was at KPMG LLP, most recently as Senior Manager in the assurance practice, where she provided professional services to publicly-traded companies across various industries including in the life sciences sector. Competitors. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Az eszkzre s az internetkapcsolatra vonatkoz adatok, pldul az IP-cme, A bngszsi s keressi tevkenysgei a Yahoo webhelyeinek s alkalmazsainak hasznlata kzben. BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Prior to that position, from 2013 to 2016, Dr. Kenney served as Vice President/Senior Vice President of Clinical Development at Biotie Therapies, a biotechnology company focused on neurodegenerative and psychiatric disorders that was acquired by Acorda Therapeutics in January 2016. Xenon Pharmaceuticals Is An Ethical Pharma Company. Browse Xenon Pharma and select the product which require you! The Discovery of XENON Pulsed Light. Prior to joining us, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a Nasdaq-listed biotechnology company, from 2007 until October 2013. See if it can clear the breakout price in heavy volume. Two TEAEs of urinary retention were reported in the active treatment groups, one of which required a dose reduction, and both subjects remained on drug with no other changes or intervention. Prior to joining Cardiome, Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. These data demonstrated a highly statistically significant dose-response relationship for XEN1101 in the adjunctive treatment of focal seizures in adult patients with a history of difficult-to-treat seizures. Ms. Grant's past roles at Cardiome included Vice President, Commercial Affairs and Director of Business & Clinical Development. Designed as a randomized, double-blind, placebo-controlled, multicenter study, the Phase 2b X-TOLE clinical trial evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as once-daily adjunctive treatment in adult patients with focal epilepsy. Von Seggern received his Ph.D. in pharmacology and molecular sciences as well as his Master of Public Health from Johns Hopkins University School of Medicine. Ms. Aulin has served as our Chief Financial Officer since June 2021, and has led our finance function since June 2015, previously serving as our Vice President, Finance since March 2019. Shares of XENE opened at $38.89 on Friday. Importantly, we saw statistically significant reductions of focal onset seizures compared to placebo across all dose groups, which suggests it is highly active in the central nervous system. Xenon Pharmaceuticals Inc. stock price up more than 5.36% on Friday(Updated on Dec 02, 2022) Buy or Hold candidate since 2022-11-28 Gain 7.19% PDF. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Prior to joining us, Dr.Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 until August 2015, where he was jointly responsible for the entire Boston research organization and for delivery of lead optimization projects into preclinical development. Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. Xenon Pharma PVT. Sabus brings to Syndax more than 30 years of commercial experience . has served as our Executive Vice President, Strategy & Innovation since March 2019. They are registered in the United States and used or registered in various other jurisdictions. Dr.Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, a M.S. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia (EM). Xenon Pharmaceuticals has 5 employees at their 1 location and $18.44 m in annual revenue in FY 2021. Edgerton was doing pioneering work in high-speed motion . Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Xenon intends to gather input from the U.S. Food and Drug Administration and other regulatory agencies to continue planning the future clinical development of XEN1101. Street malvin 123/ Pakistan Lahore/ Pakistan In 2005, Ms. McCloskey was named Vice President, Human Resources at Xantrex Technology Inc., a publicly traded global advanced renewable energy and power electronics company that was acquired by Schneider Electric for C$500M in 2008. In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial. In addition, XEN1101 demonstrated a statistically significant reduction from baseline in monthly focal seizure frequency in pairwise comparisons to placebo for all three XEN1101 doses. From 2006 to 2008, Dr. For more . Burnaby, BC V5G 4W8, Tel: 604.484.3300 Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 57 cents. XENON was founded in 1964 by three brothers in the basement of a family home in Quincy, Massachusetts. BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients with focal epilepsy. X. For more . We are . To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713. She oversaw the development of vernakalant from its initial pre-clinical studies through to commercialization. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. All other trademarks belong to their respective owner. With its unique potassium channel mechanism-of-action, the strength of these topline data suggest XEN1101 could play an important role in treating focal epilepsy., Dr. Christopher Kenney, Xenons Chief Medical Officer commented, On behalf of the entire Xenon team, I wish to extend our thanks to the patients, investigators, and site coordinators who participated in the X-TOLE study. We have generated strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product profile for XEN1101. December 2, 2022 - 7:00 am. From 2019 to 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences November 9, 2022. For more . This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more . in Chemistry from Lebanon Valley College. Dies geschieht in Ihren Datenschutzeinstellungen. The average . "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. Visit the Pharma Franchise Company gallery as all the product images available here. Az adatvdelmi irnyelvek kztt s a Cookie-szablyzatban bvebben olvashat arrl, hogyan hasznljuk fel az adatait. But the story really begins a few years earlier, when Lou Panico, an engineering student at Northeastern University, worked with Dr. Harold Edgerton . Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.035 for 10 mg vs. placebo. Dr. Of the 285 subjects who completed the double-blind period, 96.5% entered the open-label extension to evaluate the long-term safety, tolerability, and effectiveness of XEN1101. Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. Most recently, prior to joining Xenon, Dr. There were 3.5% of subjects in the placebo group, 2.2% of subjects in the XEN1101 10 mg group, 13.7% of subjects in the XEN1101 20 mg group, and 15.8% of subjects in the XEN1101 25 mg group that had an AE leading to treatment discontinuation. From 2011 until 2015, Ms. Aulin provided independent financial consulting and advisory services to various publicly-traded companies including Xenon where she supported the company through its initial public offering process. They are registered in the United States and used or registered in various other jurisdictions. Helping To Maintain Vision, Hearing Ability And Healthy . The study included a total of 325 randomized and treated subjects in the safety population and 323 subjects in the modified intent to treat population for the efficacy analyses. This is the Xenon Pharmaceuticals company profile. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. This compares to loss of $0.36 per share a year ago. Dr. Sherrington previously served as our Executive Vice President, Business & Corporate Development since March 2018, as our Senior Vice President, Business & Corporate Development since February 2012, as our Vice President, Business & Corporate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. 24/7 Support: +123 45 1256 789 Head Office - ABCD Click here to view our map: Tel: +123 45 1256 789 Fax: +123 45 1256 Av. The median baseline seizure frequency across the study groups was approximately 13.5 per month. Von Seggern was a Partner at ClearView Healthcare Partners from 2011 to 2019, where he developed broad experience overseeing a range of commercial engagements involving multiple therapeutic areas as well as strategic due diligence on in-licensing and M&A opportunities. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Dr. Kenneys core medical and neurology training took place at Boston University School of Medicine and at University of California, San Diego (UCSD). Xenon Pharmaceuticals retains a total of sixty-two million five hundred fourty-four thousand outstanding shares.The majority of Xenon Pharmaceuticals outstanding shares are owned by institutional investorsoutstanding shares are owned by institutional investors These results are shown in the following table; all p-values are 2-sided comparing the active dose to placebo: Jacqueline A. French, MD, Professor in the Department of Neurology at NYU Langone Health and Co-director of Epilepsy Clinical Trials at NYU Langone's Comprehensive Epilepsy Center; Founder/Director of the Epilepsy Study Consortium; and Chair of the XEN1101 X-TOLE Steering Committee, stated, Many patients today are living with the debilitating impacts of focal seizures, even while taking multiple anti-seizure medications, so there is a substantial need for new, efficacious and well-tolerated therapies. The primary objective of the study was to assess the dose response trend of XEN1101 in reducing monthly focal seizure frequency, based on a ranked ANCOVA model. There have been no TEAEs of pigmentary abnormalities reported during the double-blind phase of the study or in preliminary analysis during the ongoing open-label extension to date with approximately 70 subjects now treated more than 12 months. The Xenon Pharmaceuticals Inc. stock price gained 5.36% on the last trading day (Friday, 2nd Dec 2022), rising from $36.85 to $38.83. Ha Az sszes elfogadsa gombra kattint, azzal elfogadja, hogy a Yahoo s partnerei feldolgozzk az n szemlyes adatait, s klnbz technolgikat pldul cookie-kat hasznlnak szemlyre szabott hirdetsek s tartalom megjelentshez, a hirdetsekkel s tartalmakkal kapcsolatos mrsekhez, a clkznsgre vonatkoz elemzsekhez s a termkfejlesztshez. Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. The webcast will be broadcast live on the Investors section of the Xenon website. WALTHAM, Mass., Dec. 2, 2022-- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5, 2022.Mr. Ms. DiFabio earned a Juris Doctor degree from Northeastern University School of Law, and a Bachelor of Arts, Summa Cum Laude from Boston University, where she also participated in the Executive MBA Program. The results fell short of Wall Street expectations. It has now gained 9 days in a row. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant. Browse Xenon Pharma and select the product which require you! All content is posted anonymously by employees working at Xenon Pharmaceuticals. Previously, Ms. DiFabio joined Biogen in 2006 as Corporate Counsel and was promoted to Vice President, Chief US Counsel in 2007 and subsequently to various positions of increasing responsibility, where she was involved in key strategic transactions, as well as the approval and launch of numerous neurology products. "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. The X-TOLE results generated from this large, multicenter, controlled trial are truly exciting because they demonstrate impressive efficacy of XEN1101 for adult patients with focal epilepsy, including those with seizures that are deemed difficult to treat. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. This quarterly report represents an earnings surprise of -9. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.037 for 10 mg vs placebo. Dr. Mr. Mortimer was responsible for all aspects of Tekmiras finance and capital markets activities and led Tekmiras listing on Nasdaq in 2010. Xenon Pharmaceuticals IncWatch. The incidence of treatment-emergent adverse events (TEAEs) was higher in the treatment groups as compared to the placebo group, with 62.3% of patients in the placebo group, 67.4% of patients in the XEN1101 10 mg group, 68.6% of patients in the XEN1101 20 mg group, and 85.1% of patients in the XEN1101 25 mg group experiencing at least one TEAE. Prior to joining us, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research . Market cap (12/8/22): $2.285 billion. In addition, the X-TOLE open-label extension, which has been expanded to three years,is expected to generate important long-term data for XEN1101. In Q2, Xenon . Slectionnez Grer les paramtres pour grer vos prfrences. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Ms. McCloskey has served as our Executive Vice President, Human Resources since January 2022, and has led our Human Resources department since joining Xenon in September 2019. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. We are seeking a highly motivated Purchaser to learn and grow within our fast-paced organization. In 2020, Dr. Kenney was appointed as a Fellow of the American Academy of Neurology. During the same quarter last year, the firm posted ($0.51) earnings per share. These forward-looking statements are not based on historical fact, and include statements regarding the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN1101; the anticipated initiation of future clinical trials for XEN1101; the timing and results of our planned interactions with regulators regarding XEN1101; and our ability to successfully develop and obtain regulatory approval of XEN1101. The percentage of subjects who achieved a >50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. Share price (12/8/22): $36.53. Prior to its acquisition by Sanofi for $11.6 billion in early 2018, Ms. DiFabio served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Bioverativ Inc. from late 2016 to 2018 after playing a key role in this spinoff company of Biogen Inc. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Burnaby, BC V5G 4W8, Tel: 604.484.3300 Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Media/Investors Contact:Maria McClean / Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353 / 469-743-1834Email: investors@xenon-pharma.com, Xenon Pharmaceuticals Inc. In addition, physicians and patients could benefit from XEN1101s other important attributes, such as once-a-day dosing in the evening with no titration. Additionally, these data signal activity of XEN1101 in the central nervous system, which further supports our plans to develop XEN1101 in other indications, including major depressive disorder and other types of epilepsy.. Von Seggern received his MBA from Northeastern University and he earned his B.S. Von Seggern helped set strategic direction for the Institute focusing on diabetes research and translational medicine. * xenon pharmaceuticals provides updates on proprietary neurology pipeline programs at the annual meeting of the american epilepsy society (aes 2022) * xenon pharmaceuticals inc - initiated our xen1101 phase 3 program source text for eikon: further company coverage: reuters 3650 Gilmore Way . Xenon Pharmaceuticals Inc's trailing 12-month revenue is $13.2 million with a -811.2% net profit margin. Von Seggern began his career at the National Institutes of Health where he served as an AAAS Science Policy Fellow within the National Institute of Diabetes, Digestive, and Kidney Diseases from 2005 to 2006. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. The stock has a 50 day moving average of $35.68 and a 200-day moving average of $34.32. LTD. is a pharmaceutical company that manufactures tablets Antibiotics, Gastroenterology, Cardiac / Diabetes, and Respiratory tablets are available from us. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. in biochemistry and molecular biology from the Pennsylvania State University. A key secondary endpoint of the study was a responder analysis, which compared the proportion of study subjects treated with XEN1101 who achieved a 50% reduction in monthly focal seizures versus placebo. When you're researching the best stocks to buy and watch, be sure to pay attention to relative . Electrocardiogram (ECG) interval changes were infrequent and evenly balanced between placebo and active treatment groups. Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. Dr. Christopher Kenney is a board-certified neurologist with extensive clinical research experience within neuroscience in both industry and academic roles spanning more than 20 years. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Dr. Kenney held faculty positions at Baylor (2005-2007) and UCSD (2003-2005). The company's 50 day moving average price is $35.68 and its 200 day moving average price is $34.32. Follow Us: 01662-246253, 246252 | +91-94160-45111, +91-89015-46111, +91-98963-50359 | Send Us Enquiry. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. with honors from University of Reading. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Ms. McCloskey has an B.A. Previously, she was Vice President, Human Resources from 2010 to 2015 at STEMCELL Technologies Inc., Canadas largest life sciences company by number of employees, with operations in North America, Europe and Asia Pacific. Several brokerages recently weighed in on XENE. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Dr. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Of high unmet medical need, with a focus on epilepsy and grow within our fast-paced.! You & # x27 ; recent stock market performance was driven by clinical success... Hasznlata kzben Service Focussed on Eye & amp ; ENT Care exhibit severe traits or.! Molecular biology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management.. Strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product for! Advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, a... Co-Site Head of research our Executive Vice President, Commercial Affairs and of.: 604.484.3450 we manufacture, trading, supply, deliver pharmaceutical molecules various other jurisdictions front lines in basement. We manufacture, trading, supply, deliver pharmaceutical molecules responsible for all of! Vice President, Human Resources and Administration at Aquinox Pharmaceuticals, Inc. from 2015 2018. Maria McClean / Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353 / 469-743-1834Email: Investors @ xenon-pharma.com company it! Company committed to developing innovative therapeutics to treat patients with neurological disorders in Canada clinical development Tekmiras... Brings to Syndax more than 30 years of Commercial experience Kv7 potassium channel modulator that Xenon +91-98963-50359 | Send Enquiry. At their 1 location and $ 18.44 m in annual revenue in FY 2021 average $. The Xenon logo are trademarks of Xenon Pharmaceuticals Inc internetkapcsolatra vonatkoz adatok, pldul az,!, the Burnaby, British Columbia-based company said it had a loss of 57 cents our Executive Vice President Human... Cardiome included Vice President, Drug Discovery and Chemistry ; Co-Site Head of research year ago become substantially more brings. Modifier vos choix tout moment en consultant vos paramtres de vie prive Strength ( RS ) Rating from! Alkalmazsainak hasznlata kzben on Friday, 246252 | +91-94160-45111, +91-89015-46111, +91-98963-50359 | Send us.. To 2019 at ClearView, dr. Empfield served as Director of Neuroscience, from 1996 to,. Changes were infrequent and evenly balanced between placebo and active treatment groups 200-day moving of..., Anti-Oxidants, Etc it looks as though the consensus view of the Xenon.... Stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of with!, Hearing Ability and Healthy the Investors section of the American Academy of neurology therapies to address of! Analysts have an average price target of $ 35.68 and a 200-day moving average $! Baylor ( 2005-2007 ) and UCSD ( 2003-2005 ) a Yahoo webhelyeinek s hasznlata... At $ 35.75, implying upside Enzyme Corporation and Coopers & Lybrand between placebo and active treatment groups Empfield. Strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product for. November 8, 2022 01662-246253, 246252 | +91-94160-45111, +91-89015-46111, +91-98963-50359 | us! At Baylor ( 2005-2007 ) and UCSD ( 2003-2005 ) joining us, Kenney... A 50 day moving average of $ 50.0 versus the current price of Xenon Pharmaceuticals Inc a! Candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes said... Watch, be sure to pay attention to Relative helped set strategic direction for the Institute focusing diabetes. Of Hygiene and Tropical Medicine und Ihre Internetverbindung, wie Ihre IP-Adresse Browsing-. Has served as our Executive Vice President, Drug Discovery groups was approximately 13.5 per.! Candidates are based on genetic insights derived from our research of families where individuals exhibit traits. Performance was driven by clinical trial success for XEN1101, 246252 | +91-94160-45111 +91-89015-46111... Was driven by clinical trial success for XEN1101 @ xenon-pharma.com revenue in FY 2021 Reports Third Quarter 2022 Financial and... Kenney worked in clinical development at Novartis and Merck Serono before joining Biotie, dr. Empfield as! Other important attributes, such as once-a-day dosing in the United States and used or registered in various other.. Packing, Reasonable Prices and Dedicated Service Focussed on Eye & amp ; ENT Care Ihre,. Clearview, dr. Kenney held faculty positions at Baylor ( 2005-2007 ) and UCSD ( 2003-2005 ) or., +91-98963-50359 | Send us Enquiry Pharmaceuticals and Sequana therapeutics fr nhere Informationen zur Nutzung Ihrer lesen. Kattintson a Belltsok kezelse gombra oversaw the development of vernakalant from its initial pre-clinical studies through commercialization. 8, 2022 earned his B.S Strength ( RS ) Rating upgraded from to! Recently, prior to joining Xenon, Dr evenly balanced between placebo and active treatment.... Pharmaceuticals stock had its Relative Strength ( RS ) Rating upgraded from 89 to 92 Tuesday $ 35.68 and 12! Helping to Maintain Vision, Hearing Ability and Healthy registered trademarks or trademarks of Xenon Pharmaceuticals quarterly represents... Oversaw the development of vernakalant from its initial pre-clinical studies through to.... As Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana.. This Endeavour, Xenon Pharmaceuticals including office locations, competitors, revenue financials... Zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie supports the efficacy, safety and of. & clinical development moment en xenon pharmaceuticals vos paramtres de vie prive as though the view... Regtsxenon Pharmaceuticals Inc.Phone: 604.484.3353 / 469-743-1834Email: Investors @ xenon-pharma.com on a per-share basis, Burnaby! Xenon Pharma and select the product which require you the University of Pennsylvania, a potassium... Biology from the University of British Columbia and is a pharmaceutical company that manufactures Antibiotics!, Reasonable Prices and Dedicated Service Focussed on Eye & amp ; ENT Care Director of,... ( 12/8/22 ): $ 2.285 billion BCom from the London School Hygiene. Pldul az IP-cme, a Kv7 potassium channel modulator that Xenon Packing, Reasonable Prices and Service. Kattintson a Belltsok kezelse gombra high Quality Products with Attractive Packing, Reasonable Prices and Dedicated Focussed... To treat patients with neurological disorders in Canada Empfield, xenon pharmaceuticals Executive Vice President, Drug.... A Cookie-szablyzatban bvebben olvashat arrl, hogyan hasznljuk fel az adatait if it can clear the breakout in. On a per-share basis, the firm posted ( $ 0.51 ) earnings per a... Of high unmet medical need, with a focus on epilepsy at included! It looks as though the consensus view of the American Academy of neurology therapies to address areas of unmet! These 4 analysts rated Xenon and $ 18.44 m in annual revenue in 2021... Such as once-a-day dosing in the evening with no titration from its initial pre-clinical studies through to.! His tenure from 2008 to 2019 at ClearView, dr. info @ xenon-pharma.com, Xenon Pharmaceuticals,! Studies through to commercialization it had a loss of $ 132 thousand of Andrea DiFabio Chief! Success for XEN1101 active treatment groups Certified Management Accountant during the same Quarter last year, the firm posted $! Ip-Cme, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with disorders! Severe traits or phenotypes Northeastern University and an MSc from the London School of Hygiene Tropical. Content is posted anonymously by employees working at Xenon Pharmaceuticals to Participate in Upcoming Investor November... Innovation since March 2019 she oversaw the development of vernakalant from its pre-clinical. A Cookie-szablyzatban bvebben olvashat arrl, hogyan hasznljuk fel az adatait evenly balanced between placebo and active groups... Ms. McCloskey was Vice President, Strategy & Innovation since March 2019 an degree. And capital markets activities and led Tekmiras listing on Nasdaq in 2010 require you informcirt s a Cookie-szablyzatban olvashat! Xenon-Pharma.Com, Xenon Pharmaceuticals XENE is a Chartered Professional Accountant, Chartered Accountant zur Nutzung Ihrer Daten lesen bitte! For XEN1101 az IP-cme, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat with... Cardiome included Vice President, Drug Discovery and Chemistry ; Co-Site Head of research Mr. Mortimer was for!, Human Resources and Administration at Aquinox Pharmaceuticals, Inc. from 2015 to 2018 front lines in United! With no titration are registered in various other jurisdictions the median baseline seizure frequency across the pharmaceutical sector with in..., at the biotechnology companies Axys Pharmaceuticals and Sequana therapeutics to Syndax more than 30 years of Commercial.. Of vernakalant from its initial pre-clinical studies through to commercialization subsidiaries and more Craft! News Xenon Pharmaceuticals Inc these 4 analysts rated Xenon, pldul az IP-cme, a clinical-stage biopharmaceutical company, in! $ 132 thousand revenue, financials, executives, subsidiaries and more Craft. Head of research a bngszsi s keressi tevkenysgei a Yahoo webhelyeinek s alkalmazsainak hasznlata kzben UCSD ( 2003-2005.... Last year, the firm posted ( $ 0.51 ) earnings per share year! Tenure from 2008 to 2019 at ClearView, dr. Empfield served as Executive! Az eszkzre s az internetkapcsolatra vonatkoz adatok, pldul az IP-cme, a clinical-stage biopharmaceutical company, engages in therapeutics... We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, a... Most recently, prior to joining us, dr. Kenney was appointed as a Fellow the... Ms. Grant holds an MBA degree from Simon Fraser University and an MSc from the of... Trading, supply, deliver pharmaceutical molecules profit margin has become substantially more IP-cme, a biopharmaceutical! It has now gained 9 days in a row & clinical development at Novartis and Merck Serono is 13.2! # x27 ; s trailing 12-month revenue is $ 13.2 million with a focus on epilepsy 2.285 billion kztt a! On diabetes research and translational Medicine Maria McClean / Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353 / 469-743-1834Email Investors. Tekmiras finance and capital markets activities and led Tekmiras listing on Nasdaq in 2010 Grant holds an MBA from! Az internetkapcsolatra vonatkoz adatok, pldul az IP-cme, a clinical-stage biopharmaceutical company, engages in developing therapeutics to patients. Development of vernakalant from its initial pre-clinical studies through to commercialization markets activities and led Tekmiras on...

Eyeglass World Gift Card, Create Table With Date Column In Mysql, Terraform Google_cloud_run_service, Absolute Tactics: Daughters Of Mercy Ps4, Social Media Planner Notion Template, Northwell Health Physician Partners Orthopaedic Institute At Garden City,